Qtron Investments LLC Has $2.51 Million Stock Position in Abbott Laboratories $ABT

Key Points

• Qtron Investments LLC increased its stake in Abbott Laboratories by 15.0%, holding 18,893 shares worth approximately $2.5 million by the end of the first quarter.
• Abbott Laboratories reported Q2 earnings of $1.26 per share, meeting analyst expectations, with revenue of $11.14 billion, a 7.4% year-over-year increase.
• The company announced a quarterly dividend of $0.59, translating to an annual yield of 1.8%, with a dividend payout ratio of 29.57%.

Qtron Investments LLC grew its position in Abbott Laboratories (NYSE:ABT - Free Report) by 15.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 18,893 shares of the healthcare product maker's stock after buying an additional 2,463 shares during the period. Qtron Investments LLC's holdings in Abbott Laboratories were worth $2,506,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Three Seasons Wealth LLC acquired a new position in Abbott Laboratories in the 4th quarter worth $1,428,000. Kelly Financial Services LLC acquired a new position in shares of Abbott Laboratories during the first quarter worth about $216,000. Voleon Capital Management LP bought a new position in shares of Abbott Laboratories during the fourth quarter worth about $273,000. Bank Pictet & Cie Europe AG raised its position in Abbott Laboratories by 1.9% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock valued at $17,274,000 after buying an additional 2,774 shares during the last quarter. Finally, Edge Financial Advisors LLC lifted its stake in Abbott Laboratories by 3.3% in the 1st quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock valued at $336,000 after acquiring an additional 81 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares of the company's stock, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.46% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ABT shares. Wells Fargo & Company lowered their price objective on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating on the stock in a report on Friday, July 18th. Raymond James Financial lowered their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a research note on Friday, July 18th. BTIG Research lowered their price target on shares of Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a research note on Friday, July 18th. Evercore ISI raised their price objective on Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Finally, Jefferies Financial Group upgraded Abbott Laboratories from a "hold" rating to a "buy" rating and raised their price objective for the company from $143.00 to $145.00 in a report on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $144.47.

Abbott Laboratories Stock Performance

ABT stock traded down $0.4820 during mid-day trading on Thursday, hitting $131.9580. 3,979,978 shares of the company were exchanged, compared to its average volume of 6,828,092. The business has a 50 day simple moving average of $131.23 and a 200-day simple moving average of $131.25. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $229.67 billion, a PE ratio of 16.54, a price-to-earnings-growth ratio of 2.49 and a beta of 0.70. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period last year, the business posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 15th. Investors of record on Tuesday, July 15th were given a dividend of $0.59 per share. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories's dividend payout ratio is currently 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.